Enhancement of Brain d-Serine Mediates Recovery of Cognitive Function after Traumatic Brain Injury

Sigal Liraz-Zaltsman, Barbara Slusher, Dana Atrakchi-Baranes, Kineret Rosenblatt, Yael Friedman Levi, Efrat Kesner, Alcino J. Silva, Anat Biegon, Esther Shohami

Research output: Contribution to journalArticle

Abstract

Cognitive deficits, especially memory loss, are common and devastating neuropsychiatric sequelae of traumatic brain injury (TBI). The deficits may persist for years and may be accompanied by increased risk of developing early- onset dementia. Past attempts to reverse the neuropathological effects of brain injury with glutamate-N-methyl-d-aspartate (NMDA) antagonists failed to show any benefits or worsened the outcome, suggesting that activation, rather than blockage, of the NMDA receptor (NMDAR) may be useful in the subacute period after TBI and stroke. Activation of the NMDAR requires occupation of the glycine-modulatory site by co-agonists to achieve its synaptic functions. Glycine and d-serine are endogenous ligands/co-agonists of synaptic NMDARs in many areas of the mature brain. The aim of the present study was to evaluate the effect of 6-chlorobenzo(d)isoxazol-3-ol (CBIO), an inhibitor of D-amino acid oxidase (DAAO), which degrades d-serine, on cognitive outcome in a mouse model of TBI. Because treating TBI animals with CBIO elevates the endogenous levels of d-serine, we compared this novel treatment with treatment by exogenous d-serine alone and combined with CBIO. The results show that a single treatment (24 h post-injury) with CBIO in the mouse model of closed head injury significantly improves cognitive and motor function, and decreases lesion volume and the inflammatory response. Moreover, the compound proved to be neuroprotective, as the hippocampal volume and the number of neurons in hippocampal regions increased. Treatment with CBIO boosted the NR1 and phospho- NR1 subunits of the NMDAR and affected the CREB, phospho-CREB, and brain-derived neurotropic factor (BDNF) pathways. These findings render CBIO a promising, novel treatment for cognitive impairment following TBI.

Original languageEnglish (US)
Pages (from-to)1667-1680
Number of pages14
JournalJournal of Neurotrauma
Volume35
Issue number14
DOIs
StatePublished - Jul 15 2018

Fingerprint

Recovery of Function
Serine
Cognition
Brain
Glycine
D-Amino-Acid Oxidase
Closed Head Injuries
Memory Disorders
N-Methyl-D-Aspartate Receptors
Occupations
Aspartic Acid
Brain Injuries
Dementia
Glutamic Acid
Stroke
Traumatic Brain Injury
Ligands
Neurons
Wounds and Injuries

Keywords

  • CBIO; cognitive deficits; d-cycloserine; NMDARs; TBI

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Liraz-Zaltsman, S., Slusher, B., Atrakchi-Baranes, D., Rosenblatt, K., Friedman Levi, Y., Kesner, E., ... Shohami, E. (2018). Enhancement of Brain d-Serine Mediates Recovery of Cognitive Function after Traumatic Brain Injury. Journal of Neurotrauma, 35(14), 1667-1680. https://doi.org/10.1089/neu.2017.5561

Enhancement of Brain d-Serine Mediates Recovery of Cognitive Function after Traumatic Brain Injury. / Liraz-Zaltsman, Sigal; Slusher, Barbara; Atrakchi-Baranes, Dana; Rosenblatt, Kineret; Friedman Levi, Yael; Kesner, Efrat; Silva, Alcino J.; Biegon, Anat; Shohami, Esther.

In: Journal of Neurotrauma, Vol. 35, No. 14, 15.07.2018, p. 1667-1680.

Research output: Contribution to journalArticle

Liraz-Zaltsman, S, Slusher, B, Atrakchi-Baranes, D, Rosenblatt, K, Friedman Levi, Y, Kesner, E, Silva, AJ, Biegon, A & Shohami, E 2018, 'Enhancement of Brain d-Serine Mediates Recovery of Cognitive Function after Traumatic Brain Injury', Journal of Neurotrauma, vol. 35, no. 14, pp. 1667-1680. https://doi.org/10.1089/neu.2017.5561
Liraz-Zaltsman S, Slusher B, Atrakchi-Baranes D, Rosenblatt K, Friedman Levi Y, Kesner E et al. Enhancement of Brain d-Serine Mediates Recovery of Cognitive Function after Traumatic Brain Injury. Journal of Neurotrauma. 2018 Jul 15;35(14):1667-1680. https://doi.org/10.1089/neu.2017.5561
Liraz-Zaltsman, Sigal ; Slusher, Barbara ; Atrakchi-Baranes, Dana ; Rosenblatt, Kineret ; Friedman Levi, Yael ; Kesner, Efrat ; Silva, Alcino J. ; Biegon, Anat ; Shohami, Esther. / Enhancement of Brain d-Serine Mediates Recovery of Cognitive Function after Traumatic Brain Injury. In: Journal of Neurotrauma. 2018 ; Vol. 35, No. 14. pp. 1667-1680.
@article{d660e643795a49ffb6bfe907ceed97ac,
title = "Enhancement of Brain d-Serine Mediates Recovery of Cognitive Function after Traumatic Brain Injury",
abstract = "Cognitive deficits, especially memory loss, are common and devastating neuropsychiatric sequelae of traumatic brain injury (TBI). The deficits may persist for years and may be accompanied by increased risk of developing early- onset dementia. Past attempts to reverse the neuropathological effects of brain injury with glutamate-N-methyl-d-aspartate (NMDA) antagonists failed to show any benefits or worsened the outcome, suggesting that activation, rather than blockage, of the NMDA receptor (NMDAR) may be useful in the subacute period after TBI and stroke. Activation of the NMDAR requires occupation of the glycine-modulatory site by co-agonists to achieve its synaptic functions. Glycine and d-serine are endogenous ligands/co-agonists of synaptic NMDARs in many areas of the mature brain. The aim of the present study was to evaluate the effect of 6-chlorobenzo(d)isoxazol-3-ol (CBIO), an inhibitor of D-amino acid oxidase (DAAO), which degrades d-serine, on cognitive outcome in a mouse model of TBI. Because treating TBI animals with CBIO elevates the endogenous levels of d-serine, we compared this novel treatment with treatment by exogenous d-serine alone and combined with CBIO. The results show that a single treatment (24 h post-injury) with CBIO in the mouse model of closed head injury significantly improves cognitive and motor function, and decreases lesion volume and the inflammatory response. Moreover, the compound proved to be neuroprotective, as the hippocampal volume and the number of neurons in hippocampal regions increased. Treatment with CBIO boosted the NR1 and phospho- NR1 subunits of the NMDAR and affected the CREB, phospho-CREB, and brain-derived neurotropic factor (BDNF) pathways. These findings render CBIO a promising, novel treatment for cognitive impairment following TBI.",
keywords = "CBIO; cognitive deficits; d-cycloserine; NMDARs; TBI",
author = "Sigal Liraz-Zaltsman and Barbara Slusher and Dana Atrakchi-Baranes and Kineret Rosenblatt and {Friedman Levi}, Yael and Efrat Kesner and Silva, {Alcino J.} and Anat Biegon and Esther Shohami",
year = "2018",
month = "7",
day = "15",
doi = "10.1089/neu.2017.5561",
language = "English (US)",
volume = "35",
pages = "1667--1680",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "14",

}

TY - JOUR

T1 - Enhancement of Brain d-Serine Mediates Recovery of Cognitive Function after Traumatic Brain Injury

AU - Liraz-Zaltsman, Sigal

AU - Slusher, Barbara

AU - Atrakchi-Baranes, Dana

AU - Rosenblatt, Kineret

AU - Friedman Levi, Yael

AU - Kesner, Efrat

AU - Silva, Alcino J.

AU - Biegon, Anat

AU - Shohami, Esther

PY - 2018/7/15

Y1 - 2018/7/15

N2 - Cognitive deficits, especially memory loss, are common and devastating neuropsychiatric sequelae of traumatic brain injury (TBI). The deficits may persist for years and may be accompanied by increased risk of developing early- onset dementia. Past attempts to reverse the neuropathological effects of brain injury with glutamate-N-methyl-d-aspartate (NMDA) antagonists failed to show any benefits or worsened the outcome, suggesting that activation, rather than blockage, of the NMDA receptor (NMDAR) may be useful in the subacute period after TBI and stroke. Activation of the NMDAR requires occupation of the glycine-modulatory site by co-agonists to achieve its synaptic functions. Glycine and d-serine are endogenous ligands/co-agonists of synaptic NMDARs in many areas of the mature brain. The aim of the present study was to evaluate the effect of 6-chlorobenzo(d)isoxazol-3-ol (CBIO), an inhibitor of D-amino acid oxidase (DAAO), which degrades d-serine, on cognitive outcome in a mouse model of TBI. Because treating TBI animals with CBIO elevates the endogenous levels of d-serine, we compared this novel treatment with treatment by exogenous d-serine alone and combined with CBIO. The results show that a single treatment (24 h post-injury) with CBIO in the mouse model of closed head injury significantly improves cognitive and motor function, and decreases lesion volume and the inflammatory response. Moreover, the compound proved to be neuroprotective, as the hippocampal volume and the number of neurons in hippocampal regions increased. Treatment with CBIO boosted the NR1 and phospho- NR1 subunits of the NMDAR and affected the CREB, phospho-CREB, and brain-derived neurotropic factor (BDNF) pathways. These findings render CBIO a promising, novel treatment for cognitive impairment following TBI.

AB - Cognitive deficits, especially memory loss, are common and devastating neuropsychiatric sequelae of traumatic brain injury (TBI). The deficits may persist for years and may be accompanied by increased risk of developing early- onset dementia. Past attempts to reverse the neuropathological effects of brain injury with glutamate-N-methyl-d-aspartate (NMDA) antagonists failed to show any benefits or worsened the outcome, suggesting that activation, rather than blockage, of the NMDA receptor (NMDAR) may be useful in the subacute period after TBI and stroke. Activation of the NMDAR requires occupation of the glycine-modulatory site by co-agonists to achieve its synaptic functions. Glycine and d-serine are endogenous ligands/co-agonists of synaptic NMDARs in many areas of the mature brain. The aim of the present study was to evaluate the effect of 6-chlorobenzo(d)isoxazol-3-ol (CBIO), an inhibitor of D-amino acid oxidase (DAAO), which degrades d-serine, on cognitive outcome in a mouse model of TBI. Because treating TBI animals with CBIO elevates the endogenous levels of d-serine, we compared this novel treatment with treatment by exogenous d-serine alone and combined with CBIO. The results show that a single treatment (24 h post-injury) with CBIO in the mouse model of closed head injury significantly improves cognitive and motor function, and decreases lesion volume and the inflammatory response. Moreover, the compound proved to be neuroprotective, as the hippocampal volume and the number of neurons in hippocampal regions increased. Treatment with CBIO boosted the NR1 and phospho- NR1 subunits of the NMDAR and affected the CREB, phospho-CREB, and brain-derived neurotropic factor (BDNF) pathways. These findings render CBIO a promising, novel treatment for cognitive impairment following TBI.

KW - CBIO; cognitive deficits; d-cycloserine; NMDARs; TBI

UR - http://www.scopus.com/inward/record.url?scp=85049310719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049310719&partnerID=8YFLogxK

U2 - 10.1089/neu.2017.5561

DO - 10.1089/neu.2017.5561

M3 - Article

VL - 35

SP - 1667

EP - 1680

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 14

ER -